Sun Pharmaceuticals plans to focus on dermatology, post its merger with Ranbaxy Labs, expected to be completed by 2014. The company has lined-up a strategy to make dermatology its biggest segment and expects almost 38-40% of US sales to come from dermatology by FY2018.
Commenting on the same, Sarabjit Kour Nangra, VP Research, IT, Angel Broking, said, ''For the same, the company plans to ramp up its Dusa facilities in the US. After the merger, the company will generate around USD 800 million from the dermatology segment, which is expected to double, thereby also pushing up the margins. We maintain our neutral on both the stock.''